Reata Pharmaceut Stock Price, News & Analysis

RETA NASDAQ

Company Description

Reata Pharmaceut (NASDAQ: RETA) is a publicly traded pharmaceutical preparation manufacturing company in the Manufacturing sector.

RETA stock has declined 100.0% over the past year.

This page provides a comprehensive overview of RETA stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

38.1M

Shares outstanding

Reata Pharmaceut (RETA) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

September 21, 2023

-0.02%

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

acquisition

June 27, 2023

+6.97%

Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia

June 15, 2023

-0.25%

Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement

fda approval

June 13, 2023

+5.24%

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

management

June 6, 2023

-0.34%

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023

-14.23%

Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

earnings clinical trial

Reata Pharmaceut has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include acquisition, fda approval, management, earnings, clinical trial. View all RETA news →

SEC Filings

View All

No SEC filings available for RETA.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

RETA Company Profile & Sector Positioning

Reata Pharmaceut (RETA) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.